- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02466048
Efficacy and Safety of SurgiFill™ on Spinal Fusion
June 4, 2015 updated by: Sewon Cellontech Co., Ltd.
Clinical Trial to Evaluate the Efficacy and Safety of SurgiFill™ on Spinal Fusion -Comparison Between Autograft Mixed With SurgiFill™ and Autograft in Spinal Fusion-
This study was designed to investigate the safety and efficacy of SurgiFill™, a bone grafting material, in patients with spinal fusion.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Detailed Description
This study is an open-trial study.
The study will be explained to the subjects and they voluntarily agreed to participate in it.
Their eligibility to participate in the study will be checked, either the right or left side of one patient will be selected for the study group, and the other, for the control group, through randomization.
In the area for the study group, autogenous bones and SurgiFillTM will be grafted; and in the area for the control group, only the autogenous bones will be grafted.
They will be asked to follow the guidelines of the investigators during the study and to visit the hospital seven times, including for screening.
At each visit, the subjects undergo an examination with doctors, a CT scan, a X-ray, and a SPECT/CT procedure to evaluate the safety and efficacy of SurgiFill™.
(*If the subject gets surgery on the screening date, the total number of his or her visits will be six).
Study Type
Interventional
Enrollment (Anticipated)
20
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Hyun Jo Kim, Bachelor
- Phone Number: 822-460-3237
- Email: angel@swcell.com
Study Locations
-
-
-
Daejeon, Korea, Republic of, 301723
- Recruiting
- The Catholic Univ. of Korea, DaeJeon St. Mary's Hospital
-
Principal Investigator:
- Young Yul Kim, MD
-
Seoul, Korea, Republic of, 137701
- Active, not recruiting
- The Catholic Univ. of Korea, Seoul St. Mary'S Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patients who require spinal fusion
- Adult patients aged 20 or older
- Patients who voluntarily agreed to participate in this study and signed the informed consent form, and who do not fall into any of the exclusion criteria
Exclusion Criteria:
- Patients or their family members with a history of an, or an ongoing, autoimmune disease
- Patients with a history of anaphylactic response
- Patients with hypersensitivity to grafting materials
- Patients with hypersensitivity to pig protein
- Patients with osteomyelitis in the surgery area
- Patients who are pregnant, breastfeeding, or planning to become pregnant
- Patients with other tumors or a non-curable disease
- Patients with a history of radiation therapy or cancer treatment within two years (Those who show normal or insignificant test results may be enrolled in this study and receive the SurgiFill™ injection based on the investigator's judgment.)
- Patients with diabetes (Those who maintain a normal blood sugar level and did not develop complications may receive the SurgiFill™ injection based on the investigator's judgment, but the doctor's confirmation is required.)
- Patients with an infection that required hospitalization for antibiotics or the administration of antiseptic agents
- Patients who have been undergoing adrenocortical hormone therapy (Those who show normal or insignificant test results may be enrolled in this study and receive the SurgiFill™ injection based on the investigator's judgment.)
- Patients with liver, heart, or kidney disease (Those who show normal or insignificant test results may be enrolled in this study and receive the SurgiFill™ injection based on the investigator's judgment. Hypertension patients are allowed.)
- Patients who had been infected with a virus (Those who show normal or insignificant test results may be enrolled in this study and receive the SurgiFill™ injection based on the investigator's judgment.)
- Patients with chronic renal failure or an endocrine system disease (Those who show normal or insignificant test results may be enrolled in this study and receive the SurgiFill™ injection based on the investigator's judgment.)
- Patients who are considered inappropriate for participation in this study due to their condition (e.g., a mental illness) based on the investigator's judgment
- Patients who had participated in another clinical trial (limited to those who participated in other studies on fracture within the last six months.)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: SurgiFill™ on Spinal Fusion
In one side of one patient, autogenous bones and SurgiFill™ will be grafted; and in the other side, only the autogenous bones will be grafted.
|
Spinal fusion, also known as spondylodesis or spondylosyndesis, is a surgical technique used to join two or more vertebrae.
Supplementary bone tissue, from the patient (autograft), is used in conjunction with the body's natural bone growth (osteoblastic) processes to fuse the vertebrae.
Either the right or left side of one patient will be selected for the study group, and the other, for the control group, through randomization.
In the study group site, SurgiFill™ and the autogenous bone mixture shall be transplanted, whereas in the control group site, only the autogenous bone shall be transplanted.
The autogenous bones are from iliac part.
Other Names:
SurgiFill™ is a gel-type high-purity ateolcollagen for bone grafting.
SurgiFill™ is used with autogenous iliac graft for dorsolateral spinal fusion.
|
Active Comparator: Autograft on Spinal Fusion
In one side of one patient, autogenous bones and SurgiFill™ will be grafted; and in the other side, only the autogenous bones will be grafted.
|
Spinal fusion, also known as spondylodesis or spondylosyndesis, is a surgical technique used to join two or more vertebrae.
Supplementary bone tissue, from the patient (autograft), is used in conjunction with the body's natural bone growth (osteoblastic) processes to fuse the vertebrae.
Either the right or left side of one patient will be selected for the study group, and the other, for the control group, through randomization.
In the study group site, SurgiFill™ and the autogenous bone mixture shall be transplanted, whereas in the control group site, only the autogenous bone shall be transplanted.
The autogenous bones are from iliac part.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Volume change of bony fusion mass in the CT
Time Frame: 1week, 6month, and 12month
|
A CT scan shall be conducted one week, and six and 12 months, post-operatively to calculate and record the bone integration volume.
The changes in the bone integration volume shown in the CT images shall be compared and analyzed.
In other words, the mean values of the experiment group's bone integration volume shown in CT images 1week, six and 12 months post-operatively shall be compared and analyzed.
|
1week, 6month, and 12month
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Degree change of bony fusion mass in the X-ray
Time Frame: 1month, 3month, 6month, and 12month
|
A radiography shall be conducted one, three, six, and 12 months post-operatively, and at the additional unscheduled visits, and the PIs from different institutions (i.e., the Seoul St. Mary's PI and the Daejon St. Mary's PI) shall cross-evaluate the results.
The mean values of the experiment group's surgical site bone integration level shown in X-ray images one, three, six and 12 months post-operatively shall be compared and analyzed.
|
1month, 3month, 6month, and 12month
|
Value of ROI(Region of interest) in the SPECT/CT
Time Frame: 3month
|
The osteoblastic activity levels at the surgical sites of the experiment and control groups shall be compared at three months post-operatively.
|
3month
|
VAS Score change of Back pain questionnaire
Time Frame: screening, 6month and 12 month
|
The level of the pain (i.e., the lumbar pain and the pain radiating to the upper and lower extremities) shall be recorded using the VAS before the spondylodesis, and at six and 12 months post-operatively.
|
screening, 6month and 12 month
|
ODI Score change of Back pain questionnaire
Time Frame: screening, 6month and 12 month
|
Using the ODI score from the ODQ, the disturbances in the daily activities associated with the lumbar pain shall be compared before the spondylodesis, and at six and 12 months post-operatively.
|
screening, 6month and 12 month
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of abnormal blood test result of participants with adverse events as a measure of safety
Time Frame: up to 12month
|
Regardless of the clinical trial, if there are blood tests' results of participants with adverse events such as hematologic examination (WBC, RBC, Hemoglobin(Hb), Hematocrit(Hct), Platelet(PLT), ESR) and general chemistry (BUN, Creatinine(Cr), AST, ALT, CRP) closed to the day of regular visit, they shall be recorded on the CRF at screening or after spinal fusion.
If there is any abnormality of the results, the number of abnormal blood test result will be recorded, and then additionally the result shall be analyzed according to the investigator's judgment.
|
up to 12month
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Young Hoon Kim, MD, The Catholic Univ. of Korea, Seoul St. Mary'S Hospital
- Principal Investigator: Young Yul Kim, MD, The Catholic Univ. of Korea, DaeJeon St. Mary's Hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
August 1, 2013
Primary Completion (Anticipated)
October 1, 2015
Study Completion (Anticipated)
January 1, 2016
Study Registration Dates
First Submitted
June 1, 2015
First Submitted That Met QC Criteria
June 4, 2015
First Posted (Estimate)
June 9, 2015
Study Record Updates
Last Update Posted (Estimate)
June 9, 2015
Last Update Submitted That Met QC Criteria
June 4, 2015
Last Verified
June 1, 2015
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- 02SGF
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Spinal Fusion Acquired
-
Vanderbilt University Medical CenterCompletedSpinal Diseases | Spinal Stenosis | Spinal Fusion Acquired | Lesions of Lumbosacral Intervertebral DiscUnited States
-
National Taiwan University HospitalTerminatedLumbar Fusion | Lumbar Spinal Fusion SurgeryTaiwan
-
Xtant MedicalRTI SurgicalRecruitingJoint Diseases | Musculoskeletal Diseases | Spinal Stenosis | Fusion of Spine | Spine | Spinal Fusion | Spinal Disease | Spinal Instability | Sacroiliac; Fusion | Fusion of Joint | SacroiliacUnited States, Spain, Germany
-
AO Foundation, AO SpineNot yet recruiting
-
M.C. Kruyt, MD, PhDKuros BioSciences B.V.Active, not recruitingSpinal FusionNetherlands
-
Montefiore Medical CenterTerminated
-
Taipei Veterans General Hospital, TaiwanCompleted
-
Assiut UniversityUnknown
-
Children's Hospital of PhiladelphiaChildren's Anesthesiology Associates, Ltd.Completed
-
Istituto Ortopedico RizzoliRecruiting
Clinical Trials on Spinal Fusion
-
Olympus Biotech CorporationCompleted
-
University Health Network, TorontoActive, not recruitingSpinal Stenosis | SpondylolisthesisCanada
-
Stryker SpineNot yet recruitingDegenerative Disc Disease | Degenerative Scoliosis
-
University of Kansas Medical CenterScoliosis Research SocietyNot yet recruitingScoliosis | Scoliosis Kyphosis
-
University of PittsburghWithdrawnSpinal Stenosis | Degenerative Spondylolisthesis
-
Istituto Ortopedico RizzoliCompletedSurgery--Complications | Spinal Fusion | Spine DiseaseItaly
-
Mohammad ARAB MOTLAGHCompleted
-
University of Colorado, DenverCompletedScoliosisUnited States
-
Flexuspine, Inc.Completed
-
Mesoblast, Ltd.CompletedDegenerative Disc Disease | Spinal Stenosis | SpondylolisthesisUnited States